This site is intended for health professionals only

Drugs firm looks to invest in Japan


A British drug company is aiming to develop and distribute new medicines with the help of small and medium-sized Japanese firms.

GlaxoSmithKline is looking to Japan, with many medicines now well established in home markets there and winning approval.

Emerging markets make up 13% of Glaxo group sales and Japan accounts for around 4%. Glaxo’s emerging markets have seen nine-month sales of £2.1 billion and year-on-year growth of 19%.

Glaxo would not take a controlling stake in the firms with which it is hoping to work with, said the firm’s Asia-Pacific head Marc Dunoyer.

The Financial Times has reported Mr Dunoyer as claiming the focus of Glaxo will be on the medium-sized segment of Japan.

Mr Dunoyer added: “It’s about reassuring them that we’re not going to take them out, but that we have some complementary areas.”

Copyright Press Association 2010

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine